Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis

202320 citationsJournal Articlehybrid Open Access

Authors

Joseph F. Merola · Brigham and Women's Hospital

Daniel Butler · University of California, San Francisco

Thomas Mark · Leo Pharma (Denmark)

Shannon Schneider · Leo Pharma (United States)

Yestle Kim · Leo Pharma (United States)

Katrina Abuabara · University of California, San Francisco

Abstract

The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.

Topics & Keywords

Dermatology and Skin Diseases Asthma and respiratory diseases Allergic Rhinitis and Sensitization

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Dermatology

Volume 159, Issue 10, pp. 1119-1119

DOI: 10.1001/jamadermatol.2023.2626

Field-Weighted Citation Impact: 5.84